Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

erdafitinib-releasing intravesical system TAR-210

A controlled-release intravesical system consisting of a pretzel-shaped tube releasing erdafitinib, a pan fibroblast growth factor receptor (FGFR) inhibitor, with potential antineoplastic activity. Upon placement of the erdafitinib-releasing intravesical system TAR-210 into the bladder, erdafitinib is gradually and continuously released from the system over an extended period of time before being removed from the bladder. Upon release, erdafitinib targets, binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:intravesical erdafitinib TAR-210
Code name:TAR 210
TAR-210
TAR210
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search